共 36 条
- [1] Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIANEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (27) : 2520 - 2530Wang, YongjunMeng, XiaWang, AnxinXie, XueweiPan, YuesongJohnston, S. ClaiborneLi, HaoBath, Philip M.Dong, QiangXu, AndingJing, JingLin, JinxiNiu, SiyingWang, YilongZhao, XingquanLi, ZixiaoJiang, YongLi, WeiLiu, LipingXu, JieChang, LiguoWang, LihuaZhuang, XianboZhao, JinguoFeng, YefangMan, HonghaoLi, GuozhongWang, Baojun
- [2] One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA TrialNEUROLOGY, 2024, 102 (03)Meng, XiaWang, AnxinTian, XueJohnston, ClaiborneLi, HaoBath, Philip M.Xu, QinZhang, YijunXie, XueweiJing, JingLin, JinxiWang, YilongZhao, XingquanLi, ZixiaoJiang, YongLiu, LipingWang, Yongjun
- [3] Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemiaBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3335 - 3340Minderhoud, CristaOtten, Leila S.Hilkens, Pieter H. E.van den Broek, Marcel P. H.Harmsze, Ankie M.
- [4] Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/ObesitySTROKE, 2020, 51 (01) : 224 - 231Mo, JinglinChen, ZimoXu, JieWang, AnxinDai, LiyeCheng, AichunMeng, XiaLi, HaoWang, YongjunJohnston, S. ClaiborneWang, YilongZhao, XingquanWang, ZhiminXia, HaiqinLi, BinZhang, GuiruRen, XudongJi, ChunlingZhang, GuohuaLi, JianhuaLu, BohuaWang, LipingFeng, ShutaoWang, DaliTang, WeiguoLi, JuntaoZhang, HongtianLi, GuanglaiWang, BaojunChen, YuhuaLian, YingLiu, BinTeng, JunfangSui, RuboLi, LejunYuan, ZhilingZang, DaweiLu, ZunengSun, LiWang, DongHou, LiyingYuan, DongcaiCao, YongliangLi, HuiTan, XiugeWang, HuicongDu, HaisongLiu, MingyiWang, SupingLiu, Qiuwu
- [5] Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function MutationsCLINICAL DRUG INVESTIGATION, 2020, 40 (11) : 1063 - 1070Narasimhalu, KaavyaAng, Yoong KweiTan, Doreen Su YinDe Silva, Deidre AnneTan, Kelvin Bryan
- [6] Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function allelesEUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (09) : 1131 - 1140Lin, JingHan, ZhaoWang, ChunYi, XingyangChai, ZhenxiaoZhou, QiangHuang, Ruyue
- [7] Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical TrialJAMA NETWORK OPEN, 2023, 6 (06)Xie, XueweiJohnston, S. ClaiborneWang, AnxinXu, QinBath, Philip M.Pan, YuesongLi, HaoLin, JinxiWang, YilongZhao, XingquanLi, ZixiaoJiang, YongLiu, LipingXu, AndingJing, JingMeng, XiaWang, Yongjun
- [8] Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trialBMC NEUROLOGY, 2020, 20 (01)Wu, HongliangSong, HuiqunDou, LianweiGao, BoPan, YanDong, MeiChen, QiLi, JiazhenSong, LixiangLiu, ChuanyuLi, BingChu, Wenzheng
- [9] Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function allelesJOURNAL OF NEUROLOGY, 2018, 265 (10) : 2396 - 2403Yi, XingyangZhou, QiangWang, ChunLin, JingChai, Zhenxiao
- [10] Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profileANNALS OF NEUROLOGY, 2019, 86 (03) : 419 - 426Xu, JieWang, AnxinWangqin, RunqiMo, JinglinChen, ZimoDai, LiyeMeng, XiaZhao, XingquanWang, YilongLi, HaoChen, WeiXian, YingWang, Yongjun